

# Nina Kimer

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4697086/nina-kimer-publications-by-year.pdf>

**Version:** 2024-04-18

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

32  
papers

486  
citations

11  
h-index

22  
g-index

47  
ext. papers

615  
ext. citations

4.7  
avg, IF

3.7  
L-index

#	Paper	IF	Citations
32	The impact of rifaximin on inflammation and metabolism in alcoholic hepatitis: A randomized clinical trial.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0264278	3.7	0
31	Indications and methods for measuring portal hypertension in cirrhosis.. <i>Scandinavian Journal of Gastroenterology</i> , <b>2022</b> , 1-9	2.4	
30	Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation. <i>Gut</i> , <b>2021</b> , 70, 379-387	19.2	32
29	Fecal microbiota transplantation in hepatic encephalopathy: a systematic review. <i>Scandinavian Journal of Gastroenterology</i> , <b>2021</b> , 56, 560-569	2.4	6
28	Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms. <i>Seminars in Liver Disease</i> , <b>2021</b> , 41, 235-247	7.3	1
27	The Psychometric Hepatic Encephalopathy Syndrome score does not correlate with blood ammonia, endotoxins or markers of inflammation in patients with cirrhosis. <i>Translational Gastroenterology and Hepatology</i> , <b>2021</b> , 6, 8	5.2	2
26	A Danish population-based case series of patients with liver cirrhosis and coronavirus disease 2019. <i>Scandinavian Journal of Gastroenterology</i> , <b>2021</b> , 56, 453-457	2.4	0
25	Atorvastatin for prevention of disease progression and hospitalisation in liver cirrhosis: protocol for a randomised, double-blind, placebo-controlled trial. <i>BMJ Open</i> , <b>2020</b> , 10, e035284	3	3
24	Pathophysiological-based treatments of complications of cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , <b>2020</b> , 55, 383-394	2.4	1
23	Cardiodynamic state is associated with systemic inflammation and fatal acute-on-chronic liver failure. <i>Liver International</i> , <b>2020</b> , 40, 1457-1466	7.9	27
22	Prognosis of patients with ascites after PleurX insertion: an observational study. <i>Scandinavian Journal of Gastroenterology</i> , <b>2018</b> , 53, 340-344	2.4	4
21	Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: A randomized trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 307-314	4	34
20	Development and predictive validity of the cirrhosis-associated ascites symptom scale: A cohort study of 103 patients. <i>World Journal of Gastroenterology</i> , <b>2018</b> , 24, 1650-1657	5.6	1
19	Low ascitic fluid total protein levels is not associated to the development of spontaneous bacterial peritonitis in a cohort of 274 patients with cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , <b>2018</b> , 53, 200-205	2.4	3
18	No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial. <i>PLoS ONE</i> , <b>2018</b> , 13, e0203200	3.7	4
17	The royal free hospital cirrhosis glomerular filtration rate: Validation in a danish cohort. <i>Hepatology</i> , <b>2017</b> , 66, 1360-1361	11.2	2
16	Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial. <i>Hepatology</i> , <b>2017</b> , 65, 592-603	11.2	47

15	PTU-094 The Assessment of Resting Energy Expenditure in Patients with Cirrhosis Remains Problematic. <i>Gut</i> , <b>2016</b> , 65, A101.1-A101	19.2	
14	Advances in the treatment of portal hypertension in cirrhosis. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2016</b> , 10, 961-9	4.2	1
13	Beta-blockers alone or in combination with isosorbide mononitrate for secondary prevention of bleeding from gastro-esophageal varices in adults with cirrhosis and gastro-oesophageal varices. <i>The Cochrane Library</i> , <b>2016</b> ,	5.2	1
12	Research update for articles published in EJCI in 2014. <i>European Journal of Clinical Investigation</i> , <b>2016</b> , 46, 880-94	4.6	
11	Beta-blockers in cirrhosis and refractory ascites: a retrospective cohort study and review of the literature. <i>Scandinavian Journal of Gastroenterology</i> , <b>2015</b> , 50, 129-37	2.4	27
10	Rifaximin for people with hepatic encephalopathy. <i>The Cochrane Library</i> , <b>2015</b> ,	5.2	3
9	New vasoactive peptides in cirrhosis: organ extraction and relation to the vasodilatory state. <i>European Journal of Clinical Investigation</i> , <b>2014</b> , 44, 441-52	4.6	20
8	Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 40, 123-32	6.1	115
7	Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy. <i>Patient Preference and Adherence</i> , <b>2014</b> , 8, 331-8	2.4	14
6	Letter: the effects of rifaximin in hepatic encephalopathy--authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 40, 858-9	6.1	1
5	The continuous reaction times method for diagnosing, grading, and monitoring minimal/covert hepatic encephalopathy. <i>Metabolic Brain Disease</i> , <b>2013</b> , 28, 231-4	3.9	46
4	Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 36, 619-26	6.1	53
3	Letter: vaptans for the treatment of hyponatraemia and ascites in patients with cirrhosis [authors' reply]. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 36, 1104-1104	6.1	
2	Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials. <i>BMJ Open</i> , <b>2012</b> , 2,	3	25
1	Cameron lesions: an often overlooked cause of iron deficiency anaemia in patients with large hiatal hernias. <i>BMJ Case Reports</i> , <b>2010</b> , 2010,	0.9	11